Articles dans des revues avec comité de lecture (215)
12.
Taghavi, M., Stordeur, P., Collart, F., Dachy, B., Pozdzik, A., Mesquita, M., & Nortier, J. (2022). Interferon-β1a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement. Kidney International Reports. doi:10.1016/j.ekir.2022.05.00213.
Taghavi, M., Mesquita, M., David, C., Geers, C., Pozdzik, A., & Nortier, J. (2022). Clinical management of a granulomatous tubulointerstitial nephritis associated with a bilateral granulomatous anterior uveitis: A challenging case report and review of the literature
. Clinical nephrology. doi:10.5414/CN11084114.
Oullaï, A., Cubilier, E., Salaouatchi, M. T., Taghavi, M., Zouggari, Y., Nortier, J., & Mesquita, M. (2022). Iatrogenic Infective Endocarditis in Hemodialysis Patients: A Case Report and Review of the Literature. Case Reports in Nephrology, 2022, 1-6. doi:10.1155/2022/850029915.
Baudoux, T., Jadot, I., Declèves, A.-E., Antoine, M.-H., Colet, J.-M., Botton, O., De Prez, E., Pozdzik, A., Husson, C., Caron, N., & Nortier, J. (2022). Experimental Aristolochic Acid Nephropathy: A Relevant Model to Study AKI-to-CKD Transition. Frontiers in medicine, 9. doi:10.3389/fmed.2022.82287016.
Lukinich-Gruia, A. T., Nortier, J., Pavlović, N. N., Milovanović, D., Popović, M., Drăghia, L. P., Păunescu, V., & Tatu, C. A. (2022). Aristolochic acid I as an emerging biogenic contaminant involved in chronic kidney diseases: A comprehensive review on exposure pathways, environmental health issues and future challenges. Chemosphere, 297, 134111. doi:10.1016/j.chemosphere.2022.13411117.
Antoine, M.-H., Husson, C., Yankep, T., Mahria, S., Tagliatti, V., Colet, J.-M., & Nortier, J. (2022). Protective Effect of Nebivolol against Oxidative Stress Induced by Aristolochic Acids in Endothelial Cells. Toxins, 14(2). doi:10.3390/toxins1402013218.
Chraibi, S., Rosiere, R., De Prez, E., Gérard, P., Antoine, M.-H., Langer, I., Nortier, J., Remmelink, M., Amighi, K., & Wauthoz, N. (2021). Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer. Biomedicine & pharmacotherapy, 139, 111716. doi:10.1016/j.biopha.2021.11171619.
Chraibi, S., Rosiere, R., De Prez, E., Antoine, M.-H., Remmelink, M., Langer, I., Nortier, J., Amighi, K., & Wauthoz, N. (2021). Pulmonary and renal tolerance of cisplatin-based regimens combining intravenous and endotracheal routes for lung cancer treatment in mice. International journal of pharmaceutics, 599, 120425. doi:10.1016/j.ijpharm.2021.12042520.
Nortier, J., Remiche, G., Delreé, P., Nauta, J., Notermans, N. C., Vivarelli, M., Diodato, D., Solé, G., Debiec, H., & Ronco, P. (2021). Antenatal Membranous Nephropathy and Type 2 (Axonal) Charcot-Marie-Tooth With Mutations in the Metallo-Membrane Endopeptidase Gene: A Call for Family Screening and Pharmacovigilance. Kidney International Reports. doi:10.1016/j.ekir.2021.04.03421.
Youl, E. N. H., Husson, C., El Khattabi, C., El Mere, S., Declèves, A.-E., Pochet, S., Nortier, J., & Antoine, M.-H. (2020). Characterization of cytotoxic effects of aristolochic acids on the vascular endothelium. Toxicology in vitro, 65, 104811. doi:10.1016/j.tiv.2020.10481122.
Sborchia, M., De Prez, E., Antoine, M.-H., Bienfait, L., Indra, R., Valbuena, G., Phillips, D. D., Nortier, J., Stiborová, M., Keun, H. C., & Arlt, V. V. (2019). The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro. Archives of toxicology, 93(11), 3345-3366. doi:10.1007/s00204-019-02578-423.
Jelaković, B., Dika, Ž., Arlt, V. V., Stiborova, M., Pavlović, N. N., Nikolić, J., Colet, J.-M., Vanherweghem, J.-L., & Nortier, J. (2019). Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid. Seminars in nephrology, 39(3), 284-296. doi:10.1016/j.semnephrol.2019.02.007